NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 8,530 Shares

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 8,530 shares of the stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $25.02, for a total transaction of $213,420.60. Following the sale, the insider now owns 11,812,033 shares in the company, valued at approximately $295,537,065.66. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.08, for a total transaction of $834,486.84.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ:NAMS opened at $23.68 on Wednesday. NewAmsterdam Pharma has a 1-year low of $8.90 and a 1-year high of $26.35. The company has a 50 day moving average price of $18.82 and a 200 day moving average price of $18.61.

Institutional Trading of NewAmsterdam Pharma

A number of large investors have recently added to or reduced their stakes in NAMS. Banque Cantonale Vaudoise acquired a new position in NewAmsterdam Pharma in the 2nd quarter worth approximately $38,000. Quarry LP boosted its stake in NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after purchasing an additional 6,247 shares during the period. Barclays PLC boosted its stake in NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after purchasing an additional 7,199 shares during the period. Bellevue Group AG acquired a new position in NewAmsterdam Pharma in the 3rd quarter worth approximately $128,000. Finally, Rosalind Advisors Inc. acquired a new position in NewAmsterdam Pharma in the 2nd quarter worth approximately $194,000. 89.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on NAMS shares. Piper Sandler restated an “overweight” rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, November 7th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $33.80.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.